Effect of topoisomerase inhibitors and DNA-binding drugs on the cell proliferation and ultrastructure of Trypanosoma cruzi

International Journal of Antimicrobial Agents

Volumn 37, Issue 5, 2011, Pages 449-456

  Zuma, Aline Araujo ^a   Cavalcanti, Danielle Pereira ^a,b   Maia, Marina C P ^a   De Souza, Wanderley ^a,b   Motta, Maria Cristina M ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b INSTITUTO NACIONAL DE METROLOGIA   (Brazil)

Author keywords

Cell ultrastructure; DNA binding drugs; Kinetoplast; Topoisomerase inhibitors; Trypanosomatids

Indexed keywords

CAMPTOTHECIN; DIMINAZENE ACETURATE; DNA TOPOISOMERASE INHIBITOR; ENOXACIN; GYRASE INHIBITOR; KINETOPLAST DNA; MERBARONE; MITOXANTRONE; NORFLOXACIN; REBECCAMYCIN;

ARTICLE; CELL PROLIFERATION; CELL ULTRASTRUCTURE; CONTROLLED STUDY; DNA BINDING; DRUG EFFICACY; EPIMASTIGOTE; EUKARYOTE; GENE REARRANGEMENT; KINETOPLAST; KINETOPLASTIDA; NONHUMAN; PRIORITY JOURNAL; PROKARYOTE; TRYPANOSOMA CRUZI;

EID: 79953898717     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2010.11.031     Document Type: Article

References (64)

1. Wang JC. Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol 2002;3:430-40. (Pubitemid 34685700)
2. Cortes F, Pastor N, Mateos S, Dominguez I. Roles of DNA topoisomerases in chromosome segregation and mitosis. Mutat Res 2003;543:59-66. (Pubitemid 36050912)
3. Obado SO, Bot C, Nilsson D, Andersson B, Kelly JM. Repetitive DNA is associated with centromeric domains in Trypanosoma brucei but not Trypanosoma cruzi. Genome Biol 2007;8:R37.
4. Solari AJ. The 3-dimensional fine structure of the mitotic spindle in Trypanosoma cruzi. Chromosoma 1980;78:239-55. (Pubitemid 10095942)
5. Ogbadoyi E, Ersfeld K, Robinson D, Sherwin T, Gull K. Architecture of the Trypanosoma brucei nucleus during interphase and mitosis. Chromosoma 2000;108:501-13. (Pubitemid 30213907)
6. De Souza W. Basic cell biology of Trypanosoma cruzi. Curr Pharm Des 2002;8:269-85. (Pubitemid 34449883)
7. Motta MCM, De Souza W, Thiry M. Immunocytochemical detection of DNA and RNA in endosymbiont-bearing trypanosomatids. FEMS Microbiol Lett 2003;221:17-23. (Pubitemid 36407747)
8. Morris JC, Drew ME, Klingbeil MM, Motyka SA, Saxowsky TT, Wang Z, et al. Replication of kinetoplast DNA: an update for the new millennium. Int J Parasitol 2001;31:453-8. (Pubitemid 32382042)
9. Liu B, Liu Y, Motyka SA, Agbo EEC, Englund PT. Fellowship of the rings: the replication of kinetoplast DNA. Trends Parasitol 2005;21:363-9. (Pubitemid 40968137)
10. De Souza W, Cavalcanti DP. DNA-containing organelles in pathogenic protozoa: a review. Trends Cell Mol Biol 2007;2:89-104.
11. Lourenço EE, Cavalcanti DP, Assine Picchi GF, Souza W, Aurélio Krieger M, Machado Motta MC, et al. Molecular characterization of type II topoisomerase in the endosymbiont-bearing trypanosomatid Blastocrithidia culicis. FEMS Microbiol Lett 2006;257:163-70.
12. Pasion SG, Hines JC, Aebersold R, Ray DS. Molecular cloning and expression of the gene encoding the kinetoplast-associated type II DNA topoisomerase of Crithidia fasciculata. Mol Biochem Parasitol 1992;50:57-68.
13. Broccoli S, Marquis JF, Papadopoulou B, Olivier M, Drolet M. Characterization of a Leishmania donovani gene encoding a protein that closely resembles a type IB topoisomerase. Nucleic Acids Res 1999;27:2745-52. (Pubitemid 29306573)
14. Das A, Dasgupta A, Sharma S, Ghosh M, Sengupta T, Bandopadhyay S, et al. Characterisation of the gene encoding type II DNA topoisomerase from Leishmania donovani: a key molecular target in antileishmanial therapy. Nucleic Acids Res 2001;29:1844-51. (Pubitemid 32433268)
15. Hanke T, Ramiro MJ, Trigueros S, Roca J, Larraga V. Cloning, functional analysis and post-transcriptional regulation of a type II DNA topoisomerase from Leishmania infantum: a new potential target for anti-parasite drugs. Nucleic Acids Res 2003;31:4917-28. (Pubitemid 37441857)
16. Strauss PR, Wang JC. The TOP2 gene of Trypanosoma brucei: a single-copy gene that shares extensive homology with other TOP2 genes encoding eukaryotic DNA topoisomerase II. Mol Biochem Parasitol 1990;38:141-50. (Pubitemid 20008194)
17. Bodley AL, Chakraborty AK, Xie S, Burri C, Shapiro TA. An unusual type IB topoisomerase from African trypanosomes. Proc Natl Acad Sci U S A 2003;100:7539-44. (Pubitemid 36760005)
18. Douc-Rasy S, Kayser A, Riou J, Riou G. ATP-independent type II topoisomerase from trypanosomes. Proc Natl Acad Sci U S A 1986;83:7152-6. (Pubitemid 16000482)
19. Fragoso SP, Goldenberg S. Cloning and characterization of the gene encoding Trypanosoma cruzi DNA topoisomerase II. Mol Biochem Parasitol 1990;55:127-34.
20. Díaz-González R, Pérez-Pertejo Y, Prada CF, Fernández-Rubio C, Balaña-Fouce R, Reguera RM. Novel findings on trypanosomatid chemotherapy using DNA topoisomerase inhibitors. Mini Rev Med Chem 2009;9:674-86.
21. Wang JC. DNA topoisomerases. Annu Rev Biochem 1985;54:665-97. (Pubitemid 15073661)
22. Das BB, Sen N, Dasgupta SB, Ganguly A, Das R, Majumder HK. Topoisomerase research of kinetoplastid parasite Leishmania, with special reference to development of therapeutics. Indian J Med Res 2006;123:221-32. (Pubitemid 43905565)
23. Hsiang YH, Lihou MG, Liu LF. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 1989;49:5077-82. (Pubitemid 19239347)
24. D'Arpa P, Beardmore C, Liu LF. Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons. Cancer Res 1990;50:6919-24. (Pubitemid 20361091)
25. 34cdc2/cyclin B. Cancer Res 1992;52:1823-9.
26. Teicher BA. Next generation topoisomerase I inhibitors: rationale and biomarker strategies. Biochem Pharmacol 2008;75:1262-71. (Pubitemid 351305209)
27. Drake FH, Hofmann GA, Bartus HF, Mattern MR, Crooke ST, Mirabelli CK. Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II. Biochemistry 1989;28:8154-60. (Pubitemid 19252897)
28. Fortune JM, Osheroff N. Merbarone inhibits the catalytic activity of human topoisomerase IIα by blocking DNA cleavage. J Biol Chem 1998;273:17643-50. (Pubitemid 28355102)
29. Potter AJ, Rabinovitch PS. The cell cycle phases of DNA damage and repair initiated by topoisomerase II-targeting chemotherapeutic drugs. Mutat Res 2005;72:27-44. (Pubitemid 40403652)
30. Woynarowski JM, Chapman WG, Napier C, Herzig MC, Juniewicz P. Sequence- and region-specificity of oxaliplatin adducts in naked and cellular DNA. Mol Pharmacol 1998;54:770-7. (Pubitemid 28523169)
31. Larsen AK, Escargueil AE, Skladanowsky A. Catalytic topoisomerase II inhibitors in cancer therapy. Pharmacol Ther 2003;99:167-81. (Pubitemid 36897748)
32. Palchaudhuri R, Hergenrother PJ. DNA as a target for anticancer compounds: methods to determine the mode of binding and the mechanism of action. Curr Opin Biotechnol 2007;18:497-503.
33. Shapiro TA, Englund PT. Selective cleavage of kinetoplast DNA minicircles promoted by antitrypanosomal drugs. Proc Natl Acad Sci U S A 1990;87:950-4.
34. Portugal J. Berenil acts as a poison of eukaryotic topoisomerase II. FEBS Lett 1994;344:136-8. (Pubitemid 24154625)
35. Singh R, Siddiqui KA, Valenzuela MS, Majumder HK. Kinetoplast DNA minicircle binding proteins in a Leishmania spp: interference of protein DNA interaction by berenil. Indian J Biochem Biophys 1995;32:437-41.
36. Camargo EP. Growth and differentiation in Trypanosoma cruzi. I. Origin of metacyclic trypanosomes in liquid media. Rev Inst Med Trop Sao Paulo 1964;6:93-100.
37. Warren LG. Metabolism of Schizotrypanum cruzi Chagas. I. Effect of culture age and substrate concentration on respiratory rate. J Parasitol 1960;46:529-39.
38. Bodley AL, Shapiro TA. Molecular and cytotoxic effects of camptothecin, a topoisomerase I inhibitor, on trypanosomes and Leishmania. Proc Natl Acad Sci U S A 1995;92:3726-30.
39. Cavalcanti DP, Fragoso SP, Goldenberg S, De Souza W, Motta MCM. The effect of topoisomerase II inhibitors on the kinetoplast ultrastructure. Parasitol Res 2004;94:439-48. (Pubitemid 40104523)
40. Marminon C, Anizon F, Moreau P, Pfeiffer B, Pierre A, Golsteyn RM, et al. Rebeccamycin derivatives as dual DNA-damaging agents and potent checkpoint kinase 1 inhibitors. Mol Pharmacol 2008;74:1620-9.
41. Cavalcanti DP, Thiry M, De Souza W, Motta MCM. The kinetoplast ultrastructural organization of endosymbiont-bearing trypanosomatids as revealed by deep-etching, cytochemical and immunocytochemical analysis. Histochem Cell Biol 2008;130:1177-85.
42. Montaner B, Castillo-Avila W, Martinell M, Ollinger R, Aymami J, Giralt E, et al. DNA interaction and dual topoisomerase I and II inhibition properties of the anti-tumor drug prodigiosin. Toxicol Sci 2005;85:870-9. (Pubitemid 40846861)
43. Diáz-González R, Pérez-Pertejo Y, Prada CF, Fernández-Rubio C, Balaña-Fouce R, Reguera RM. Novel findings on trypanosomatid chemotherapy using DNA topoisomerase inhibitors. Mini Rev Med Chem 2009;9:674-86.
44. Bakshi RP, Shapiro TA. RNA interference of Trypanosoma brucei topoisomerase IB: both subunits are essential. Mol Biochem Parasitol 2004;136:249-55. (Pubitemid 38757993)
45. Wang Z, Drew ME, Morris JC, Englund PT. Asymmetrical division of the kinetoplast DNA network of the trypanosome. EMBO J 2002;21:4998-5005.
46. Nenortas E, Bodley AL, Shapiro TA. DNA topoisomerases: a new twist for antiparasitic chemotherapy. Biochim Biophys Acta 1998;140:349-54. (Pubitemid 28475114)
47. Das A, Dasgupta A, Sengupta T, Majumder HK. Topoisomerases of kinetoplastid parasites as potential chemotherapeutic targets. Trends Parasitol 2004;20:381-6.
48. Reguera RM, Pérez-Pertejo Y, Redondo CM, Díaz- González R, Balaña-Fouce R. Type I DNA topoisomerase from protozoan pathogens as a potential target for anti-tumoral drugs. Medicina (B Aires) 2007;67:747-57 [in Spanish].
49. Das A, Sengupta T, Majumder HK. Topoisomerases of kinetoplastid parasites: why so fascinating? Mol Microbiol 2006;62:1-11.
50. Li T-K, Liu LF. Tumor cell death induced by topoisomerase-targeting drugs. Annu Rev Pharmacol Toxicol 2001;41:53-77. (Pubitemid 32385882)
51. Takemura H, Rao VA, Sordet O, Furuta T, Miao ZH, Meng L, et al. Defective Mre11-dependent activation of Chk2 by ataxia telangiectasia mutated in colorectal carcinoma cells in response to replication-dependent DNA double strand breaks. J Biol Chem 2006;13:30814-23. (Pubitemid 44582136)
52. Stracker TH, Morales M, Couto SS, Hussein H, Petrini JH. The carboxy terminus of NBS1 is required for induction of apoptosis by the MRE11 complex. Nature 2007;10:218-21. (Pubitemid 46763076)
53. Sen N, Das BB, Ganguly A, Mukherjee T, Tripathi G, Bandgyopadhyay S, et al. Camptothecin induced mitochondrial dysfunction leading to programmed cell death in unicellular hemoflagellate Leishmania donovani. Cell Death Differ 2004;11:924-36. (Pubitemid 39139751)
54. Heywood P, Weinman D. Mitosis in the hemoflagellate Trypanosoma cyclops. J Protozool 1978;25:287-92. (Pubitemid 9049390)
55. Nardelli SC, Da Cunha JPC, Motta MCM, Schenkman S. Distinct acetylation of Trypanosoma cruzi histone H4 during cell cycle, parasite differentiation, and after DNA damage. Chromosoma 2009;118:487-99.
56. Bodley AL, Wani MC, Wall ME, Shapiro TA. Antitrypanosomal activity of camptothecin analogs. Structure-activity correlations. Biochem Pharmacol 1995;50:937-42.
57. Deterding A, Dungey FA, Thompson K, Steverding D. Anti-trypanosomal activities of DNA topoisomerase inhibitors. Acta Trop 2005;93:311-6. (Pubitemid 40348835)
58. Gonzales-Perdomo M, Castro SL, Meirelles MNSL, Goldenberg S. Trypanosoma cruzi proliferation and differentiation are blocked by topoisomerase II inhibitors. Antimicrob Agents Chemother 1990;34:1707-14. (Pubitemid 20259498)
59. Anderson VE, Gootz TD, Osheroff N. Topoisomerase IV catalysis and the mechanism of quinolone action. J Biol Chem 1998;10:17879-85. (Pubitemid 28355135)
60. Croft SL, Hogg J. Limited activity of bacterial DNA topoisomerase II inhibitors against Leishmania donovani and Trypanosoma cruzi amastigotes in vitro. Trans R Soc Trop Med Hyg 1988;82:856.
61. Nenortas E, Burri C, Shapiro TA. Antitrypanosomal activity of fluoroquinolones. Antimicrob Agents Chemother 1999;43:2066-8. (Pubitemid 29395212)
62. Nenortas E, Kulikowicz T, Burri C, Shapiro TA. Antitrypanosomal activities of fluoroquinolones with pyrrolidinyl substitutions. Antimicrob Agents Chemother 2003;47:3015-7. (Pubitemid 37040291)
63. Woynarowski JM, McHugh M, Sigmund RD, Beerman TA. Modulation of topoisomerase II catalytic activity by DNA minor groove binding agents distamycin, Hoechst 33258, and 4′,6-diamidine-2-phenylindole. Mol Pharmacol 1989;35:177-82.
64. Batista DGJ, Pacheco MGO, Kumar A, Branowska D, Ismail MA, Hu L, et al. Biological, ultrastructural effect and subcellular localization of aromatic diamidines in Trypanosoma cruzi. Parasitology 2010;137:251-9.